NOT FDA-APPROVED

MGF (Mechano Growth Factor)

A natural splice variant of IGF-1 that your muscles release after damaging exercise. The synthetic version is used in bodybuilding for satellite cell activation. Half-life so short it's essentially a one-shot signal.

The 30-second read

MGF (Mechano Growth Factor) is a natural splice variant of the IGF-1 gene called IGF-1Ec. Your muscles produce it locally after mechanical loading or damage, the kind that happens during heavy resistance training. Its biological role is activating satellite cells (the resident stem cells of muscle tissue) that drive muscle repair and hypertrophy. The synthetic form is used in bodybuilding and research contexts as a post-workout site-injection to amplify that natural signal. Plasma half-life is extremely short, minutes, which is why MGF is dosed near the target muscle and timed close to training. Not FDA-approved. PEG-MGF is the pegylated, longer-acting version more practical for systemic effects.

Why this peptide is on people's radar

MGF has an unusually clean biological story. The IGF-1 gene can be alternatively spliced into different isoforms. IGF-1Ea (the dominant liver-produced systemic form), IGF-1Eb, and IGF-1Ec. The Ec splice variant is the one that gets produced primarily in muscle tissue in response to mechanical loading or damage. It was named "Mechano Growth Factor" because researchers, particularly Geoffrey Goldspink at University College London, showed that this splice variant is what links the mechanical signal of resistance training to satellite cell activation and muscle repair.

Synthetic MGF takes that natural endogenous signal and offers it as an exogenous peptide. The bodybuilding rationale: inject MGF near a worked muscle right after training to amplify the satellite cell activation that's already underway. The research rationale: study muscle-repair biology with controlled exogenous MGF delivery.

What both communities run into is the same pharmacological constraint: synthetic MGF has a plasma half-life on the order of minutes. The natural local muscle release is autocrine/paracrine, produced and used right at the tissue. Trying to recreate that with subcutaneous injection means working with a very short window of bioavailability. That's why PEG-MGF exists, pegylating the molecule extends the half-life enough to support practical systemic dosing. Most modern research-peptide protocols use PEG-MGF rather than native MGF for that reason.

What people are usually trying to do with it

People exploring MGF are usually focused on:

  • Amplifying post-workout satellite cell activation in worked muscles
  • Recovery and hypertrophy support tied to specific training sessions
  • Site-injection for targeted muscle effects
  • An anabolic option that mimics a natural muscle-tissue signal
  • Recovery from muscle injury

What the science actually shows

Plain-English summary:

IGF-1Ec splice variant biology

Multiple studies confirm IGF-1Ec is upregulated in muscle after mechanical loading and damage. The natural endogenous role in satellite cell activation and muscle repair is well-characterized.1

Satellite cell activation

Animal and cell-culture studies show MGF activates satellite cells (muscle resident stem cells) and supports their proliferation, supporting muscle repair and growth.2

Pharmacokinetics

Plasma half-life is on the order of 5 to 7 minutes, extremely short, much shorter than native IGF-1's already-short half-life. The natural endogenous role is local autocrine/paracrine, not systemic, which is consistent with the rapid clearance.3

What hasn't been demonstrated

FDA approval. Rigorous human clinical trials of synthetic MGF for muscle hypertrophy. That site-injection MGF produces meaningfully better outcomes than the body's natural endogenous MGF release after training. That short-half-life systemic dosing produces enough sustained receptor activation to drive measurable hypertrophy.

The honest read

What's solid:

The natural IGF-1Ec / MGF biology is real and well-characterized. Geoffrey Goldspink's research on muscle-tissue mechanotransduction and the role of MGF in satellite cell activation is legitimate science.

What's still unproven:

Whether synthetic exogenous MGF meaningfully amplifies the body's natural post-training MGF release. The body produces MGF locally in response to training; whether adding more from outside provides a benefit beyond what training already does isn't rigorously established.

What's hyped beyond the evidence:

"Site injection grows muscle locally" framings, same as for IGF-DES, the localized-effect claim is more bodybuilding-lore than evidence. The extremely short half-life means most of an MGF dose is gone within minutes, which limits both the localized claim and any sustained anabolic effect. Most modern protocols use PEG-MGF for that reason.

Things to know if you're looking into it

  • Compared to PEG-MGF: native MGF has a much shorter half-life and is typically used for site-injection close to training. PEG-MGF's pegylation extends the half-life to ~48 hours, making systemic dosing practical. Most modern research-peptide MGF use is actually PEG-MGF.
  • How it's used in research: typically intramuscular site injection near a worked muscle, immediately post-training. The very short half-life makes timing important.
  • Same cancer-biology considerations as IGF-1 LR3 and IGF-DES: as an IGF-1 family peptide, MGF carries the same theoretical concerns about cumulative IGF-1 receptor activation and tumor biology. Family history of hormonally-driven cancers is a meaningful contraindication.
  • Athlete bans: MGF is on the World Anti-Doping Agency banned list as part of the IGF-1 family. Competitive athletes will test positive.
  • Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list as of 2026.
  • Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

What people often ask

Is MGF a form of IGF-1?

It's a splice variant of the same gene. The IGF-1 gene gets alternatively spliced into multiple isoforms. IGF-1Ea (the systemic liver form), Eb, and Ec. MGF is the IGF-1Ec splice variant, the one your muscles produce locally after mechanical loading.

How is it different from IGF-1 LR3 or IGF-DES?

Different molecule. LR3 and DES are modified forms of native IGF-1 (Ea splice variant) engineered for longer half-life or higher receptor potency. MGF is a different splice variant entirely, with a different C-terminal extension. The C-terminal "E peptide" of MGF appears to have unique satellite-cell-activating effects that the Ea splice variant doesn't share.

Should I use MGF or PEG-MGF?

Most modern research-peptide protocols use PEG-MGF because of the practical half-life issue. Native MGF is essentially limited to site-injection close to training. PEG-MGF's longer half-life supports broader dosing strategies. For most users, PEG-MGF is the more practical choice.

Why is the half-life so short?

Because MGF's natural endogenous role is local autocrine/paracrine signaling, released by muscle tissue, used right at that tissue. The body never needs MGF to circulate widely, so there's no biological reason for it to have a long half-life. The synthetic version inherits the same short clearance.

Is it FDA-approved?

No. Not approved for any indication. Not currently on the FDA Category 2 list.

Does the body produce its own MGF after training?

Yes. The whole reason researchers identified the IGF-1Ec splice variant is that its expression is upregulated in muscle after resistance training. So if you train hard enough, you're already producing your own MGF, exogenous synthetic MGF is layered on top of that natural response.

Will I test positive on a drug test?

Yes. MGF is on the WADA banned list. Competitive athletes will test positive.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Not currently on the FDA Category 2 list. On the World Anti-Doping Agency Prohibited List as part of the IGF-1 family. Status updates land here when they happen.

Want to go deeper? Mechanism, IGF-1Ec splice biology, dosing, side-effect profile, and references.

Background

MGF (Mechano Growth Factor) is the synthetic equivalent of the IGF-1Ec splice variant, a 24-amino-acid C-terminal peptide unique to the Ec isoform of human IGF-1. The IGF-1 gene is alternatively spliced into Ea, Eb, and Ec isoforms. IGF-1Ea is the dominant liver-produced systemic form. IGF-1Ec is preferentially expressed in muscle tissue in response to mechanical loading. The Ec isoform was characterized by Geoffrey Goldspink and colleagues at University College London in the 1990s in the context of muscle hypertrophy and adaptation research.

Mechanism of action

Satellite cell activation

MGF activates muscle satellite cells (resident muscle stem cells) and drives their proliferation. This expands the pool of myogenic progenitors available for muscle repair and hypertrophy after training.

Distinct from IGF-1Ea action

The C-terminal E peptide of IGF-1Ec appears to have unique signaling properties beyond binding the IGF-1 receptor, including effects on satellite cell biology that the IGF-1Ea splice variant doesn't share to the same degree.

Local autocrine/paracrine signaling

Endogenous MGF is produced and used locally at the muscle tissue level. The synthetic version retains the same rapid plasma clearance, minutes, consistent with a peptide whose evolutionary role is local rather than systemic.

Why systemic dosing is hard

The very short half-life makes practical systemic administration of native MGF essentially impossible, the molecule is gone before it can reach distant muscle tissue. This is the gap that PEG-MGF addresses through pegylation.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision.

Site injection (research-community range): 100 to 200 mcg per dose, intramuscular, near a worked muscle, immediately post-training.

Treatment duration: typically used acutely tied to specific training sessions rather than as continuous daily dosing.

Side effects and safety profile

Reported in research-community use:

  • Mild injection-site reactions, more notable with intramuscular site injection
  • Hypoglycemia is less of an issue than with LR3 or DES because of the extremely short half-life and lower systemic exposure
  • Mild fatigue or local soreness (uncommon)

Theoretical concerns: same IGF-1 family cancer-biology considerations apply, though the rapid clearance produces less cumulative IGF-1 receptor activation than chronic LR3 or DES use would.

References

  1. Yang S, Alnaqeeb M, Simpson H, Goldspink G. (1996). "Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch." J Muscle Res Cell Motil, 17(4), 487–495. PubMed
  2. Hill M, Goldspink G. (2003). "Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage." J Physiol, 549(Pt 2), 409–418. PubMed
  3. Goldspink G. (2005). "Mechanical signals, IGF-I gene splicing, and muscle adaptation." Physiology, 20(4), 232–238. PubMed
  4. Philippou A, Maridaki M, Halapas A, Koutsilieris M. (2007). "The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology." In Vivo, 21(1), 45–54. PubMed
For educational and research purposes only. This is not medical advice. MGF is not FDA-approved. Same IGF-1 family cancer-biology considerations apply. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.